Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
01.08.2018 17:40:51

NEURONES: Organic growth up 5.1% in 1st half 2018

PRESS INFORMATION

Nanterre, August 1, 2018 (after trading)

Heading: Revenues H1 2018

Organic growth up 5.1% in 1st half 2018

(in millions of euros) H1 2017

restated IFRS15 (*)
H1 2018

IFRS15 (*)
growth of which organic
Revenues 239.2 243.1 + 1.6% + 5.1%

Achievements

With constant structures and similar accounting method (IFRS15), organic growth is up 5.1% for the first six months of 2018.

The operating profit for the half-year is 8.5% of revenues (**), compared with 8.6% for the first half of 2017.

In comparison with the 2017 reference document available in the Finance section on the Neurones website (www.neurones.net, "Finance" page), there were no significant changes in the financial situation.

Outlook

With constant structures, NEURONES forecasts the following for 2018:

-  close to €490m in revenues (IFRS15*),

-  an operating profit of approximately 9% of revenues.

(*)   Application of IFRS15 reduced the group's revenues by around €9 million in 2017 and 2018, naturally with no impact on operating profit.

(**) Unaudited and after inclusion of 0.3% expenses related to bonus shares.

About NEURONES

With over 5,100 employees, the NEURONES group specializes in Consulting (Management, Organization and Digital) and IT Services (Infrastructures and Applications). It supports its clients in their digital transformation and information system outsourcing projects.

Euronext Paris (compartment B - NRO) - Enternext Tech 40 - SRD medium values

www.neurones.net

Press Relations:

Florence Gillier Communication

Sabine GROSDIDIER

+33 1 41 18 85 55

sabineg@fgcom.fr
 

NEURONES

Matthieu VAUTIER

+33 1 41 37 41 37

rp@neurones.net
Investor Relations:

NEURONES

Paul-César BONNEL

+33 1 41 37 41 37

investisseurs@neurones.net



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NEURONES via Globenewswire

Nachrichten zu NeuronesAct.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu NeuronesAct.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

NeuronesAct. 44,40 0,68% NeuronesAct.